ArticleMicrobial cell factories2020
Metabolic engineering of Escherichia coli for optimized biosynthesis of nicotinamide mononucleotide, a noncanonical redox cofactor.
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 67 citations in OpenAlex.
- Reprogramming the Rossmann fold signature motif creates orthogonal redox biocatalysts.Nature communications · 2026Article
- Metabolic Engineering ofMicroorganisms · 2026Article
- Continuous production of nicotinamide mononucleotide by engineered Escherichia coli: effect of dilution rate and glucose feeding.Bioprocess and biosystems engineering · 2026Article
- Reprogramming the Rossmann Fold Signature Motif Creates Orthogonal Redox Biocatalysts.bioRxiv : the preprint server for biology · 2025Article
- Enhancing production of nicotinamide mononucleotide by metabolic engineering and flow cytometry screening of Escherichia coli.Biotechnology letters · 2025Article
- Network of nicotinamide mononucleotide biosynthesis: substrate tracking, rate-limiting enzyme, and regulatory strategy.Synthetic and systems biotechnology · 2025Review
- Biological properties, synthetic pathways and anti-aging mechanisms of nicotinamide mononucleotide (NMN): Research progress and challenges.Biogerontology · 2025Review
- Shifting redox reaction equilibria on demand using an orthogonal redox cofactor.Nature chemical biology · 2024Article
- Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide.Nutrients · 2024Review
- EngineeringACS catalysis · 2024Article
- Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging.Aging and disease · 2024Review
- Biosynthesis of β-nicotinamide mononucleotide from glucose via a new pathway inFrontiers in microbiology · 2024Article
- Harnessing lactic acid bacteria for nicotinamide mononucleotide biosynthesis: a review of strategies and future directions.Frontiers in microbiology · 2024Review
- Semirational engineering ofApplied and environmental microbiology · 2023Article
- The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.Advances in nutrition (Bethesda, Md.) · 2023Review
- Technology and functional insights into the nicotinamide mononucleotide for human health.Applied microbiology and biotechnology · 2023Review
- Orthogonal glycolytic pathway enables directed evolution of noncanonical cofactor oxidase.Nature communications · 2022Article
- Directed evolution of phosphite dehydrogenase to cycle noncanonical redox cofactors via universal growth selection platform.Nature communications · 2022Article
- Engineering Embden-Meyerhof-Parnas Glycolysis to Generate Noncanonical Reducing Power.ACS catalysis · 2022Article
- Enzymatic synthesis of high-titer nicotinamide mononucleotide with a new nicotinamide riboside kinase and an efficient ATP regeneration system.Bioresources and bioprocessing · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNoncanonical redox cofactors are emerging as important tools in cell-free biosynthesis to increase the economic viability, to enable exquisite control, and to expand the range of chemistries accessible. However, these noncanonical redox cofactors need to be biologically synthesized to achieve full integration with renewable biomanufacturing processes.
resultsIn this work, we engineered Escherichia coli cells to biosynthesize the noncanonical cofactor nicotinamide mononucleotide (NMN
conclusionThese results further the understanding of effective production and integration of NMN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.